BBI 2000

Drug Profile

BBI 2000

Alternative Names: BBI-2000; BBI-2111

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syngenta
  • Developer Brickell Biotech
  • Class Anti-inflammatories; Antiallergics; Peptides; Thioredoxins
  • Mechanism of Action Cell movement inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic contact dermatitis

Most Recent Events

  • 24 May 2018 Phase-II clinical trials in Allergic contact dermatitis (Topical) (Brickell Biotech pipeline, May 2018)
  • 24 May 2018 Brickell Biotech plans a proof of concept trial for Allergic contact dermatitis in late 2018 (Brickell Biotech pipeline, May 2018)
  • 24 May 2017 Brickell Biotech completes a phase I trial in Allergic contact dermatitis (In volunteers) in Canada (NCT03089775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top